⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

November 1, 1989JNCI Journal of the National Cancer Institute

Decreased Testicular Cancer Risk in Men Born in Wartime

View at Publisher

Ask AI

Bookmark

Share

Abstract

HENRIK MØLLER; Decreased Testicular Cancer Risk in Men Born in Wartime, JNCI: Journal of the National Cancer Institute, Volume 81, Issue 21, 1 November 1989, Pa

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Henrik Møller (1989) studied this question.

synapsesocial.com/papers/6ab8b642d072061247137707 https://doi.org/10.1093/jnci/81.21.1668-a

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Employment after curative breast cancer treatment: the breast cancer and the workforce cohort studyJNCI Journal of the National Cancer Institute · Fri,
2A clinical model incorporating early lymphocyte dynamics in HER2-positive breast cancerJNCI Journal of the National Cancer Institute · Fri,
3Efficacy and toxicity of antibody-drug conjugates in older adults with breast cancer: A systematic review and meta-analysisJNCI Journal of the National Cancer Institute · Fri,
4Foundation models for cancer: advancing diagnosis, prognosis, and treatment response—an NCI workshop reportJNCI Journal of the National Cancer Institute · Wed,
5Novel framework for the validation of intermediate clinical endpoints in oncology real-world dataJNCI Journal of the National Cancer Institute · Mon,

More from JNCI Journal of the National Cancer Institute

Effects of private health insurance coverage gains on colorectal cancer outcomes: a modeling studyMon,
Identification of prediagnostic proteomic biomarkers for colon and rectal cancer in 3 prospective cohortsMon,
Time trends of human papillomavirus-attributable head and neck cancers: the BROADEN studyMon,
Colonoscopy screening outcomes in Lynch syndrome and differential colorectal cancer paths among MLH1 / MSH2 carriersMon,
Cardio-protection and monitoring for early phase clinical trials: Recommendations from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortiumMon,